LYMPHOMA & MYELOMA CONNECT is an international group of experts in the field of hematological malignancies and is an initiative of COR2ED. The group discusses the latest scientific and clinical insights, identifies educational needs, and develops educational programmes to support healthcare professionals globally to provide the best possible care to their patients.
LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Karyopharm Therapeutics and Menarini Stemline Oncology.
What’s new from LYMPHOMA & MYELOMA CONNECT
Video
Early relapsed/refractory multiple myeloma (RRMM): best practices in management
A 3-part video series on managing early RRMM from leading medical experts
Experts
Dr Elena Zamagni, Dr Fredrik Schjesvold, Dr Joseph Mikhael-
Downloadable
Resources -
4 MIN
-
Sep 2024
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)
Medical experts discuss the latest learnings from clinical practice
Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter-
Downloadable
Resources -
MIN
-
Jun 2024
Conference update
Episode
6
of 6
Listen to Expert Insights on Late-Breaking Data from ASCO 2023
Episode 6: Lymphoma Update: SWOG S1826 trial
Experts
Dr Mansoor Raza Mirza, Dr Paolo Tarantino, Prof. Alexey V Danilov, Prof. Mark Socinski, Prof. Evan Yu, Prof. Thomas Powles, Assoc. Prof. Gerald Prager-
2 MIN
-
Jun 2023
Update From ASH 2022
Highlights from the ASH Annual Meeting
Experts
Dr Matthew J. Matasar-
4 MIN
-
Dec 2022
Update from ASCO 2022 – Myeloma
Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)
Experts
Asst. Prof. Hans Lee-
2 MIN
-
May 2022
Podcast
Episode
3
of 3
Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics
Episode 3: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics
Experts
Assoc. Prof. María Victoria Mateos, Dr Alexander M Lesokhin-
Downloadable
Resources -
MIN
-
Mar 2022
